Select Language
Free Registration
Save Product

Biotinylated Human CD19 (20-291) Protein, Fc,Avitag™, premium grade

COADS MS
DS

Customer Reviews
Cat. No. / Size
Price
Qty
CD9-H82F6-25ug
$515.00
CD9-H82F6-200ug
$2450.00
ETA of in-stock products:2 business days
Sub-Total$ 0
Customize Product
Quote Inquiry

Product Details

  • Synonym

    CD19, B4, CVID3, MGC12802

  • Source

    Biotinylated Human CD19 (20-291), Fc,Avitag, premium grade (CD9-H82F6) is expressed from human 293 cells (HEK293). It contains AA Pro 20 - Lys 291 (Accession # P15391-1).

    Predicted N-terminus: Pro

    It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage. When ready to transition into later clinical phases, we also offer a custom GMP protein service that tailors to your needs. We will work with you to customize and develop a GMP-grade product in accordance with your requests that also meets the requirements for raw and ancillary materials use in cell manufacturing of cell-based therapies.

    Request for sequence

  • Molecular Characterization

    CD19 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a human IgG1 Fc tag at the C-terminus, followed by an Avi tag (Avitag™).

    The protein has a calculated MW of 59.0 kDa. The protein migrates as 70-80 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the HABA assay / binding ELISA.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Sterility

    Negative

  • Mycoplasma

    Negative

  • Purity

    >95% as determined by SDS-PAGE.

    >90% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Storage

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.

  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Customers Also Viewed

Performance Data

  • SDS-PAGE

    CD19 SDS-PAGE

    Biotinylated Human CD19 (20-291), Fc,Avitag, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    CD19 SEC-MALS

    The purity of Biotinylated Human CD19 (20-291), Fc,Avitag, premium grade (Cat. No. CD9-H82F6) is more than 90% and the molecular weight of this protein is around 130-160 kDa verified by SEC-MALS.

    Report

  • Bioactivity-FACS

    CD19 FACS

    2e5 of anti-CD19 CAR-293 cells were stained with 100 μL of 3 μg/mL of Biotinylated Human CD19 (20-291), Fc,Avitag, premium grade (Cat. No. CD9-H82F6) and negative control protein respectively, washed and then followed by PE-SA and analyzed with FACS (QC tested).

    Protocol

  • Bioactivity-ELISA

    CD19 ELISA

    Immobilized Biotinylated Human CD19 (20-291), Fc,Avitag, premium grade (Cat. No. CD9-H82F6) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-Human CD19 Antibody, Mouse IgG2a with a linear range of 0.1-4 ng/mL (QC tested).

    Protocol

Customer Reviews
Writing Reviews

Background

B-lymphocyte antigen CD19 is also known as CD19 (Cluster of Differentiation 19), is a single-pass type I membrane protein which contains two Ig-like C2-type (immunoglobulin-like) domains. CD19 is expressed on follicular dendritic cells and B cells. In fact, it is present on B cells from earliest recognizable B-lineage cells during development to B-cell blasts but is lost on maturation to plasma cells. It primarily acts as a B cell co-receptor in conjunction with CD21 and CD81. Upon activation, the cytoplasmic tail of CD19 becomes phosphorylated, which leads to binding by Src-family kinases and recruitment of PI-3 kinase. As on T cells, several surface molecules form the antigen receptor and form a complex on B lymphocytes. The (almost) B cell-specific CD19 phosphoglycoprotein is one of these molecules. The others are CD21 and CD81. These surface immunoglobulin (sIg)-associated molecules facilitate signal transduction. On living B cells, anti-immunoglobulin antibody mimicking exogenous antigen causes CD19 to bind to sIg and internalize with it. The reverse process has not been demonstrated, suggesting that formation of this receptor complex is antigen-induced. This molecular association has been confirmed by chemical studies. Mutations in CD19 are associated with severe immunodeficiency syndromes characterized by diminished antibody production. CD19 has been shown to interact with: CD81, CD82, Complement receptor 2, and VAV2.

Recent Advances

 
Drug Development Progress
  • English Name：

    B-lymphocyte antigen CD19

  • Category：

  • Approved Drugs：

    12 Details

  • Drugs in Clinical Trials：

    310 Details

  • Highest Development Stage：

    NDA/BLA

Contact Us
Drug Candidate Licensing
More
  • Basic Product Information
  • Product Details
  • Customers Also Viewed
  • Performance Data
  • Customer Reviews
  • Background